Head-to-head · WeighScore
Dollar Dad Club vs No BS RX
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 59.7/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the Dollar Dad Club review and the No BS RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Dollar Dad Club vs Strut Health and Edessa vs No BS RX compare each of them with another graded program, and the list of alternatives to Dollar Dad Club ranks the programs closest to Dollar Dad Club on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Dollar Dad Club | No BS RX |
|---|---|---|
| WeighScore | 59.7/100 | 82.8/100 |
| Grade | C | B− |
| Site position | #365 | #23 |
| Semaglutide | Advertised $69/mo; conflicting plan cards leave selected term and recurring price unverified | $149/mo advertised for standard compounded injection; low-dose priced separately |
| Tirzepatide | Advertised $99/mo; competing plan and dose prices require confirmation | $225/mo advertised for standard compounded injection; low-dose priced separately |
| Coverage | Coverage not published | Confirm program availability for your state |
| Brand-name access | Not confirmed | Yes |
| Oral / sublingual | Yes | Yes |
Site position #365 · C
Strengths
- Offers compounded injections and a separate oral program
- Plan descriptions include provider review, medication, supplies and shipping
- Terms identify Beleaf LLC and permit pharmacy choice before ordering
What to consider
- Current $69/$99 injection headlines conflict with promotional and dose-specific plan cards
- Six- and twelve-month early exits reprice supplied medication at regular shorter-plan rates, not pro rata
- Refund policy uses both dispatch and earlier pharmacy-processing boundaries
- Oral daily-tablet page includes inconsistent weekly-dose instructions; exact formulation needs confirmation
- Assigned pharmacy, state eligibility and recurring charges remain unverified
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.